Recombinant tissue plasminogen activator (rTPA) management for first onset acute Ischemic Stroke with covid -19 and non-covid -19 patients
In this study we compare the efficacy and safety of Tissue plasminogen activator (rTPA) in acute ischemic stroke (AIS) patients with or without Covid-19 infection.
Source: Journal of Stroke and Cerebrovascular Diseases - Category: Neurology Authors: Eman M Khedr, Ahmed Abdelwarith, Gehad M Moussa, Mostafa Saber Source Type: research
More News: Coronavirus | COVID-19 | Ischemic Stroke | Neurology | Stroke | Study | Thrombolytic Therapy | Thrombosis